Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905627 | 1.00 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6298159 | 0.99 | — | — | |
| Hydrochloric Acid SCHEMBL4049104 | 0.99 | — | — | |
| SCHEMBL4042051 | 0.82 | — | — | |
| SCHEMBL4041775 | 0.82 | — | — | |
| SCHEMBL4040404 | 0.81 | HTR2C (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL4040402 | 0.81 | HTR2C (0.36) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4043431 | 0.81 | — | — | |
| SCHEMBL4037690 | 0.81 | — | — | |
| SCHEMBL4037692 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | claimed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | claimed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1846410-B1 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1846410-A2 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | Bristol-Myers Squibb Company (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7238702-B2 | Dihydroquinazolinones as 5HT modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2006086464-A2 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060178386-A1 | Dihydroquinazolinones as 5HT modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | HTR2A 140/4885HTR2C 158/4885HTR2B 366/4885 |
| US-20060178386-A1 | Dihydroquinazolinones as 5HT modulators | HTR3B, HTR2C, HTR2B | HTR2A 6/4885HTR2C 2/4885HTR2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.